Hormone therapy might be underutilized in women with early menopause

Human Reproduction

Volumn 30, Issue 4, 2015, Pages 848-852

  Lindh Astrand L ^a   Hoffmann, M ^a   Jarvstrat L ^a   Fredriksson, M ^a   Hammar, M ^a   Spetz Holm, A C ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

early menopause; estrogen; hormone therapy

Indexed keywords

CONJUGATED ESTROGEN; CONTRACEPTIVE AGENT; DIENOGEST; DIENOGEST PLUS ESTROGEN; DROSPIRENONE PLUS ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN PLUS LEVONORGESTREL; ESTROGEN PLUS MEDROXYPROGESTERONE; ESTROGEN PLUS NORETHISTERONE; LEVONORGESTREL; MEDROXYPROGESTERONE; NORETHISTERONE; TIBOLONE; UNCLASSIFIED DRUG; HORMONE;

ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; EARLY MENOPAUSE; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GYNECOLOGIST; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; OVARIECTOMY; PRESCRIPTION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SWEDEN; THROMBOEMBOLISM; TREATMENT DURATION; CARDIOVASCULAR DISEASES; ESTROGEN THERAPY; MIDDLE AGED; PROCEDURES; REGISTER; SOCIAL CLASS; TREATMENT OUTCOME; UTILIZATION;

ADULT; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONES; HUMANS; MENOPAUSE, PREMATURE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SOCIAL CLASS; SWEDEN; TREATMENT OUTCOME;

EID: 84926609715     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dev017     Document Type: Article

References (19)

1. Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009; 48:27-33.
2. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
3. Coulam C, Adamson S, Annegers J. Incidence of premature ovarian failure. Obstet Gynecol 1986;67:604-606.
4. Deniz G, Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Treatment of premature menopause in breast cancer patients. Acta Chir Belg 2007; 107:263-266.
5. Harlap S. The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol 1992;166:1986-1992.
6. Hoffmann M, Hammar M, Kjellgren KI, Lindh-Astrand L, Brynhildsen J. Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. Maturitas 2005;52:11-17.
7. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613.
8. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990;97:1080-1086.
9. Järvsträt L, Spetz Holm AC, Lindh-Astrand L, Hoffmann MJ, Fredrikson MG, Hammar ML. Use of hormone therapy in Swedish women aged 80 years or older. Menopause 2015;22:275-278.
10. Lokkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT. The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. Maturitas 2006;53:226-233.
11. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450.
12. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
13. Okeke T, Anyaehie U, Ezenyeaku C. Premature menopause. Ann Med Health Sci Res 2013;3:90-95.
14. Popat VB, Calis KA, Kalantaridou SN, Vanderhoof VH, Koziol D, Troendle JF, Reynolds JC, Nelson LM. Bone mineraldensityinyoung women withprimary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J Clin Endocrinol Metab 2014;99:3418-3426. Epub 2014 Jun 6.
15. Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr, Roger VL, Melton LJ III, Rocca WA. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009a;16:15-23.
16. Rivera CM, Grossardt BR, Rhodes DJ, Rocca WA. Increased mortality for neurological and mental diseases following early bilateral oophorectomy. Neuroepidemiology 2009b;33:32-40.
17. Rossouw JE, Anderson GL, Prentice RL, La Croix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
18. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas 2010;65:161-166.
19. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad-Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M. The new Swedish Prescribed Drug Register-opportunities for pharmacoepide-miological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-735.